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Although endogenous recruitment of adult neural
stem cells has been proposed as a therapeutic
strategy, clinical approaches for achieving this are
lacking. Here, we show that metformin, a widely
used drug, promotes neurogenesis and enhances
spatial memory formation. Specifically, we show
that an atypical PKC-CBP pathway is essential for
the normal genesis of neurons from neural precur-
sors and that metformin activates this pathway to
promote rodent and human neurogenesis in culture.
Metformin also enhances neurogenesis in the adult
mouse brain in a CBP-dependent fashion, and in so
doing enhances spatial reversal learning in the water
maze. Thus, metformin, by activating an aPKC-CBP
pathway, recruits neural stem cells and enhances
neural function, thereby providing a candidate phar-
macological approach for nervous system therapy.
INTRODUCTION
Adult neural stem cells and the new neurons that they generate
play key functional roles in the mammalian brain (Zhao et al.,
2008). Intriguingly, growing evidence indicates that neural stem
cells are also recruited in an attempt at endogenous repair in
the injured or degenerating brain (Kernie and Parent, 2010), find-
ings that suggest that if we could exogenously recruit adult
neural stem cells, thismight provide a novel therapeutic strategy.
Some studies have attempted to do this with growth factors, but
this approach has not been successful in part because of difficul-
ties in delivering growth factors to the nervous system and in part
because these are broadly active and highly potent biological
entities (Miller and Kaplan, 2012).One alternative to growth factors are small molecules that
promote stem cell self-renewal and/or differentiation either as
identified by high throughput screens (Li et al., 2012) or by
defining relevant signaling pathways. With regard to the latter,
we recently showed that the CBP transcriptional coactivator
was necessary for optimal differentiation of embryonic neural
precursors and that CBP ability to promote differentiation
required phosphorylation by atypical protein kinase C (aPKC)
(Wang et al., 2010). Intriguingly, in liver cells, the aPKC-CBP
pathway is downstream of AMP kinase (AMPK) and is activated
by the AMPK-activating drugmetformin (He et al., 2009), which is
widely used to treat type II diabetes and other metabolic
syndromes. These findings therefore suggest that metformin
might activate aPKCs in neural stem cells and, in so doing, allow
their recruitment in the adult brain.
Here, we have tested this idea. We define distinct roles for
aPKCs i and z in regulating the neural precursor to neuron tran-
sition and show that aPKCz regulates the genesis of neurons in
a CBP-dependent fashion. Moreover, we show that metformin
can activate this aPKC-CBP pathway to promote rodent and
human neurogenesis in culture. Finally, we show that metformin
has similar actions in the adult mouse CNS in vivo, acting to
increase the genesis of neurons in the hippocampus in a CBP-
dependent fashion and, in so doing, to enhance spatial reversal
learning in a water maze task. Thus, metformin represents a
candidate pharmacological approach for recruitment of neural
stem cells in the adult human brain, a strategy that might be of
therapeutic value for the injured or degenerating nervous system.
RESULTS
Atypical Protein Kinase C Isoforms Differentially
Regulate the Radial Precursor to Neuron Transition
during Embryonic Cortical Neurogenesis
We previously showed that two aPKC isoforms, i and z, are
expressed in the developing murine cortex and that aPKCz isCell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc. 23
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Figure 1. aPKCs z and i Regulate Cortical
Precursor Differentiation into Neurons in
Culture
(A) Western blot analysis of HEK293 cells co-
transfected with a flag-tagged expression con-
struct for murine aPKCz (top) or aPKCi (bottom)
and either a scrambled shRNA (Scr) or one of two
shRNAs specific for aPKCz (top) or aPKCi
(bottom). Blots were probed for the flag tag (top) or
aPKCi (bottom) and reprobed for total ERK as
a loading control.
(B–D) Precursors were cotransfected with plas-
mids encoding EGFP and aPKCz, aPKCi, or
scrambled shRNAs for 2 days, immunostained for
EGFP (C, green) and cleaved caspase-3 (C, red),
and counterstained with Hoechst 33258 (C, blue)
and the percentage of transfected cells with con-
densed, apoptotic morphology (B) or expressing
cleaved caspase-3 (CC3) (D) was determined. In
(C) the same field is shown in both panels, and
arrows denote a double-labeled cell with a
condensed nucleus. p > 0.05; n = 3 independent
experiments, pooled. Scale bars represent 25 mm.
(E) Percentage of transfected, phospho-histone
H3-positive cells in cultures cotransfected with
EGFP and aPKCz, aPKCi, or scrambled shRNAs
for 2 days. p > 0.05; n = 3 independent experi-
ments, pooled.
(F) Precursors cotransfected with plasmids en-
coding EGFP and scrambled shRNA for 3 days,
immunostained for EGFP (green) and bIII-tubulin
(red), and counterstained with Hoechst 33258
(blue). The same field is shown in both panels, and
arrows denote double-labeled cells. Scale bars
represent 50 mm.
(G) Percentage of transfected, bIII-tubulin-positive
cells in precursor cultures cotransfected with
EGFP and aPKCz, aPKCi or scrambled shRNAs
for 3 days, as shown in (F). **p < 0.01; n = 4–5
independent experiments, pooled.
(H and I) Percentage of bIII-tubulin-positive trans-
fected neurons in precursor cultures 3 days after
cotransfection with aPKCi (H) or aPKCz (I) shRNA
and expression plasmids for EGFP and human
aPKCi (H) or aPKCz (I). The number of transfected neurons under control conditions was normalized to 100%. *p < 0.05; n = 3 independent experiments
each, pooled.
(J) Percentage of bIII-tubulin-positive cells in precursor cultures treated with myristoylated aPKC pseudosubstrate peptide inhibitor (2 mM) or water, as a control,
for 3 days. *p < 0.05; n = 4 independent experiments, pooled.
(K) Percentage of transfected, bIII-tubulin-positive cells in precursors cotransfected with EGFP and aPKCz plus aPKCi shRNAs, or with scrambled shRNA for
3 days, and analyzed as shown in (F). *p < 0.05; n = 3 independent experiments, pooled.
Error bars represent SEM. See also Figure S1.
Cell Stem Cell
Metformin Enhances Neurogenesis via aPKC-CBPessential for the genesis of glial cells from cultured neural precur-
sors (Wang et al., 2010). To ask whether aPKCswere also essen-
tial for neurogenesis, we studied cultured radial precursors from
the E12.5 murine cortex that generate neurons first and glia
second. We knocked down the aPKC isoforms in these precur-
sors with previously characterized shRNAs (He et al., 2009;
Wang et al., 2010), confirming their efficacy with two experi-
ments. First, we cotransfected them individually into HEK293
cells along with aPKCi or z expression plasmids, as relevant;
western blots confirmed that the shRNAs effectively knocked
down aPKC isoform expression relative to either a scrambled
shRNA or no shRNA (Figure 1A). Second, we cotransfected
each shRNA with an EGFP expression plasmid into cultured
cortical precursors and immunostained them 2 days later for24 Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc.aPKCi or z; the proportion of EGFP-positive cells expressing
no or low aPKCi or z was increased by approximately 2-fold
and 1.7-fold, respectively (Figures S1A and S1B available
online).
We then used these shRNAs to ask what role aPKCs played in
neural precursors. Cortical precursors were cotransfected with
an EGFP plasmid and either aPKCz shRNA#1 or aPKCi
shRNA#1 and analyzed 3 days later when many precursors
had differentiated into neurons. As a control, we used a scram-
bled shRNA that had no effect on cortical precursor biology
(Figure S1C). Quantification of condensed, apoptotic nuclei
(Figures 1B and 1C) and immunostaining for the apoptotic
marker cleaved caspase-3 (Figures 1C and 1D) indicated that
neither aPKC isoform was essential for cell survival. Similarly,
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Figure 2. Genetic Knockdown of aPKCs
Differentially Regulates Neural Precursor
Differentiation In Vivo
(A) Immunostaining with an antibody for total aPKC
(red; Hoechst 33258 counterstain is blue) on
coronal E12 cortical sections. The boxed area is
enlarged at right to show aPKC immunoreactivity
adjacent to the ventricle (V). Control is immuno-
stained with secondary antibody alone. Scale bars
represent 50 mm (left) and 25 mm (right).
(B–N) E13/14 cortices were electroporated with
plasmids encoding EGFP and aPKCz (E–J), aPKCi
(K–N), or scrambled shRNAs and sectioned coro-
nally for analysis 3 days later.
(B) Immunostaining for EGFP (white) in sections
electroporated with scrambled (left) or aPKCz
(right) shRNAs. White lines denote region bound-
aries. V denotes the ventricle. Scale bars represent
250 mm.
(C) Percentage of EGFP-positive cells within
VZ/SVZ, IZ, and CP as shown in (B). *p < 0.05;
***p < 0.001; n = 4–6 brains each.
(D) Immunostaining for EGFP (green) and CC3
(red; blue is Hoechst 33258) in the section elec-
troporatedwith scrambled shRNA. The boxed area
at left is shown at higher magnification at right.
Arrows denote a CC3-positive cell. V denotes the
ventricle. Scale bars represent 100 mm (left) and
25 mm (right).
(E) Confocal images of cortical sections electro-
porated with aPKCz shRNA (top) or scrambled
shRNA (all other panels) and double-labeled for
EGFP (green) and Ki67, HuD, Pax6, Sox2, or Tbr2,
as indicated (all red). In all cases, the same field is
shown in left and right panels, and the arrows
denote double-labeled cells. All panels show the
VZ/SVZ except for the HuDpanel, which shows the
CP. Scale bars represent 20 mm.
(F–J) Percentage of transfected Ki67-positive (F),
HuD-positive (G), Pax6-positive (H), Sox2-positive
(I), or Tbr2-positive (J) cells in cortices electro-
porated with aPKCz or scrambled shRNAs and
immunostained as in (E). **p < 0.01; ***p < 0.001;
n = 4–6 brains each.
(K–N) Percentage of transfected, HuD-positive
(K), Pax6-positive (L), Sox2-positive (M), or Tbr2-
positive (N) cells in cortices electroporated with
aPKCi or scrambled shRNAs and immunostained
as in (E). *p < 0.05; **p < 0.01; n = 4–6 brains each.
Error bars represent SEM. See also Figure S2.
Cell Stem Cell
Metformin Enhances Neurogenesis via aPKC-CBPimmunostaining of transfected cultures for two markers of prolif-
erating cells, phosphohistone H3 (Figure 1E) and Ki67 (Fig-
ure S1D), demonstrated that cell division was not altered by
either shRNA. In contrast, both aPKC isoforms were necessary
for neurogenesis; knockdown of either aPKCz or aPKCi signifi-
cantly decreased the proportion of bIII-tubulin-positive newly
born neurons (Figures 1F and 1G).
We confirmed the specificity of this neurogenesis phenotype in
three ways. First, we showed that aPKCi shRNA#2 and aPKCz
shRNA#2 also decreased neurogenesis without affecting pro-
liferation (Figures S1E and S1F). Second, we rescued the
decreased neurogenesis by coincidently expressing human
aPKCior z, which are not targetedby themurine shRNAs (Figures
1H and 1I). Third, we inhibited total aPKC activity by using amyristoylated aPKC pseudosubstrate peptide inhibitor that is
efficacious in cortical precursors (Wang et al., 2010) and that
blocks the activity of both isoforms. This inhibitor significantly
reduced neurogenesis at 3 days (Figure 1J), and the magnitude
of this decrease was similar to that seen when precursors were
cotransfected with aPKCi and z shRNAs together (Figure 1K).
Thus, aPKCs normally regulate cortical neurogenesis in culture.
We therefore asked whether aPKCs also regulate cortical neu-
rogenesis in vivo; our previous biochemical analysis showed
cortical expression of both aPKC isoforms from E12, the earliest
time point examined, until birth (Wang et al., 2010). Immunos-
taining with a pan-aPKC antibody demonstrated that aPKCs
were apically localized in precursors that line the ventricles in
the E12 cortex (Figure 2A), as previously reported (Imai et al.,Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc. 25
Cell Stem Cell
Metformin Enhances Neurogenesis via aPKC-CBP2006; Costa et al., 2008), and consistent with an association
between aPKCi and the apical polarity complex in radial precur-
sors (Costa et al., 2008; Bultje et al., 2009). We therefore
knocked down each aPKC isoform individually in radial precur-
sors by in utero electroporation of the shRNAs together with
a cytoplasmic EGFP expression plasmid into E13/14 cortices
(Wang et al., 2010). This approach electroporates radial precur-
sors that line the ventricle, many of which will then differentiate
into neurons in the ventricular zone/subventricular zone (VZ/
SVZ), prior to their migration through the intermediate zone (IZ)
to the cortical plate (CP). At later time points the same precursor
pool generates glial cells and adult neural stem cells.
Analysis of cortices 3 days postelectroporation demonstrated
that both aPKC isoforms regulated the radial precursor to neuron
transition but that they did so in different ways. For aPKCz, anal-
ysis of the location of electroporated cells showed a decrease in
EGFP-positive cells within the CP and a small increase in the IZ
(Figures 2B and 2C). To ask about the cellular basis of this
phenotype, we characterized the survival, proliferation and
identity of the electroporated cells. Immunostaining for cleaved
caspase-3 (Figure 2D) showed that survival was unaffected,
with only five to ten positive cells per cortical section with or
without aPKCz knockdown. Immunostaining for Ki67 (Figure 2E)
showed that the percentage of proliferating cells was also
unchanged (Figure 2F). In contrast, immunostaining for the
neuron-specific protein HuD demonstrated that aPKCz knock-
down reduced the number of EGFP-positive neurons (Figures
2E and 2G), thereby explaining the decrease in EGFP-positive
cells in the CP. To ask whether undifferentiated precursors
were coincidentally increased, we immunostained sections for
the radial precursor markers Pax6 and Sox2 (Figure 2E); aPKCz
knockdown increased both populations (Figures 2H and 2I). In
contrast, immunostaining for Tbr2, which marks the basal
progenitor transit-amplifying cells in this system, showed that
they were unaffected (Figures 2E and 2J). Thus, aPKCz pro-
motes differentiation of radial precursors into neurons in vivo.
A similar analysis for the aPKCi knockdown showed that it did
not affect the distribution of EGFP-positive transfected cells
(Figures S2A and S2B), nor did it affect cleaved caspase-3-
positive cells. There was also no significant change in HuD-posi-
tive electroporated neurons, although there was a trend toward
a decrease (Figure 2K). In contrast, aPKCi knockdown signifi-
cantly altered precursor populations. Pax6-positive and Sox2-
positive radial precursors were decreased (Figures 2L and 2M),
and Tbr2-positive basal progenitors were correspondingly
increased (Figure 2N). Thus, aPKCi functions to maintain radial
precursors and to inhibit their transition to basal progenitors,
consistent with its role in the polarity complex.
These data argue that aPKCs z and i control cortical neuro-
genesis via distinct mechanisms. In this regard, we previously
showed that aPKCz but not i regulated cortical gliogenesis by
phosphorylating and activating CBP (Wang et al., 2010). We
confirmed this previous result (Figures S1G and S1H) and then
determined whether CBP was also downstream of aPKCz with
regard to neurogenesis. We did this genetically, asking whether
a CBP phosphomimic that was mutated at the aPKC phosphor-
ylation site could rescue the decrease in neurogenesis caused
by aPKCz knockdown. For comparison, we examined aPKCi
knockdown. Quantification of cotransfected precursor cultures26 Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc.showed that the CBP phosphomimic rescued the decreased
neurogenesis seen with aPKCz but not aPKCi knockdown (Fig-
ure 3A). Thus, aPKCz enhances neurogenesis by activating CBP.
Metformin Activates Atypical PKC and Promotes
Neurogenesis in Rodent Cortical Precursors
Our data indicate that the aPKC-CBP pathway promotes neuro-
genesis. Because metformin activates this pathway in liver cells
(He et al., 2009), we asked whether it would also do so in cortical
precursors. Precursors were cultured for 1 day and exposed to
15 mMmetformin for 15 min, and lysates were probed with anti-
bodies for total aPKC and for aPKC phosphorylated at threonine
403, which is critical for kinase activity (Messerschmidt et al.,
2005). Metformin caused a modest but reproducible increase
in aPKC threonine 403/410 phosphorylation (Figure 3B). We
then cultured precursors in 500 mM metformin and asked how
this affected their biology. Analysis of cleaved caspase-3 and
cells with condensed nuclei at 2 days showed that cell survival
was unaffected by metformin (Figures 3C and 3D). Similarly,
cell division, as monitored by phosphohistone H3-positive cells
at 2 days, was unchanged (Figure 3E). In contrast, metformin
almost doubled the percentage of bIII-tubulin-positive neurons
present at 3 days (Figures 3F and 3G), an increase that was
accompanied by a corresponding decrease in the proportion
of Pax6-positive (Figure 3H) and Sox2-positive (Figure 3I)
precursors.
We next asked whether the metformin-induced increase in
neurogenesis required the aPKC-CBP pathway. Initially, we
asked about the aPKCs, transfecting precursors with shRNAs
for both isoforms at levels that did not significantly decrease
basal neurogenesis (Figure 3J), presumably because the remain-
ing aPKC levels were sufficient for maintenance. We then
cultured these transfected precursors with or without metformin.
Analysis of transfected bIII-tubulin-positive neurons after 3 days
(Figure 3J) showed that metformin increased neurogenesis and
that the aPKC shRNAs inhibited metformin-induced neurogene-
sis. We then asked about CBP, by using previously character-
ized siRNAs (Wang et al., 2010). Precursors were transfected
with CBP or scrambled siRNA and were cultured in metformin
for 3 days. CBP knockdown completely inhibited the metfor-
min-induced increase in neurogenesis (Figure 3K).
These results indicate that metformin activates the aPKC-CBP
pathway in cortical precursors, thereby enhancing neurogene-
sis. We therefore asked whether it also promotes gliogenesis,
as would be predicted by our previous results (Wang et al.,
2010). To do this, we added metformin to precursor cultures
on day 2 and analyzed them on day 7, when endogenous glio-
genesis has commenced. Metformin increased genesis of both
GFAP-positive astrocytes and A2B5-positive oligodendrocyte
precursors (Figure 3L), suggesting that metformin activates an
aPKC-CBP pathway to generally promote cortical precursor
differentiation.
Finally, we asked whether metformin affected cortical pre-
cursor differentiation in vivo by electroporating E13/14 embryos
with an EGFP expression construct and by treating their mothers
with metformin daily for 4 days, starting 1 day prior to electropo-
ration. Analysis 3 days postelectroporation showed that the
location of EGFP-positive cells was similar in progeny of control
versus metformin-treated mothers (Figures S3A and S3B).
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Figure 3. Metformin Activates an aPKC-CBP
Pathway to Promote Genesis of Neurons
from Murine Cortical Precursors
(A) Percentage of transfected, bIII-tubulin-positive
cells in precursor cultures 3 days after cotrans-
fectionwith EGFPandaPKCz, aPKCi, or scrambled
shRNAs plus or minus a CBP phosphomimic. The
number of neurons generated with the scrambled
shRNA was normalized to 100%. *p < 0.05;
**p < 0.01; n = 3 independent experiments.
(B) Western blot for aPKC z/i phosphorylation at
T410/403 in cortical precursors treated with water
(as a control) or metformin (15 mM) for 15 min. Blot
was reprobed for total aPKC and for ERKs as a
loading control. The graph shows the relative level
of phosphorylation of aPKC normalized to total
aPKC, as determined by densitometry. *p < 0.05;
n = 3 independent experiments.
(C–I) Cultured cortical precursors were treated with
500 mM metformin (Met) or water (Control) for 2
(C–E) or 3 (F–I) days.
(C and D) Percentage of transfected cells that were
positive for cleaved caspase-3 (CC3) (C) or that
displayedcondensed, apoptotic nuclei (D). p>0.05;
n = 3 independent experiments, pooled.
(E) Percentage of cells positive for the proliferation
marker phospho-histone H3. p > 0.05; n = 3 inde-
pendent experiments, pooled.
(F) Immunostaining (red; blue is Hoechst 33258 to
show nuclei) for bIII-tubulin in precursor cultures
treated with water or metformin for 3 days. Scale
bars represent 25 mm.
(G) Percentage of bIII-tubulin-positive neurons in
precursor cultures as shown in (F), where the
number of neurons under control conditions was
normalized to 100%. *p < 0.05; n = 5 independent
experiments, pooled.
(H and I) Percentage of Pax6-positive precursors
(H) or Sox2-positive precursors (I) in cultures
treated as in (F). *p < 0.05; **p < 0.01; n = 4 inde-
pendent experiments, pooled.
(J and K) Percentage of bIII-tubulin-positive
neurons in cultures treated for 2 days with 500 mM
metformin or water (Control) 18 hr after co-
transfection with EGFP and either (J) aPKCz plus
aPKCi shRNAs or (K) CBP siRNAs. As controls,
cells were cotransfected with scrambled shRNA or
siRNA. In (J), only half as much aPKC shRNA was
used as in Figure 1K. *p < 0.05; **p < 0.01; n = 3 (J)
or 4 (K) independent experiments, pooled.
(L) Percentage of GFAP-positive and A2B5-positive cells in precursor cultures treated with water or 500 mMmetformin from day 2 to day 7, where the numbers of
astrocytes or oligodendrocyte precursors under control conditions were normalized to 100%. *p < 0.05; n = 3 independent experiments, pooled.
Error bars represent SEM. See also Figure S3.
Cell Stem Cell
Metformin Enhances Neurogenesis via aPKC-CBPAlthough the proportion of Pax6-positive precursors was
unchanged (Figure S3D), there was a small but significant
increase in HuD-positive neurons (Figure S3C), consistent with
the culture data.
Metformin Enhances Neurogenesis from Human
ESC-Derived Neural Precursors
If metformin could promote neurogenesis from human neural
stem cells as it does from murine, then this might serve as the
basis for a potential therapeutic strategy. To address this possi-
bility, we developed a method for generating forebrain neuralprecursors fromhuman embryonic stem cells (hESCs). Embryoid
bodies (EBs) were generated from hESCs and were treated for
12 days with Dorsomorphin, an inhibitor of BMP signaling, and
SB43152, an inhibitor of Lefty/Activin/TGF-b signaling (Cham-
bers et al., 2009; Zhou et al., 2010). These differentiated EBs
were dissociated and adhered to a laminin-coated surface.
Immunostaining showed that approximately 60%–70% of the
freshly plated cells expressed Pax6 (Figure 4A). In addition,
they expressed other markers consistent with a forebrain pre-
cursor identity including nestin (Figure 4B), the radial precursor
marker BLBP (data not shown), and the cortical marker Emx1Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc. 27
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A Figure 4. Metformin Activates aPKCs to
Enhance the Genesis of Neurons from
hESC-Derived Forebrain Neural Precursors
(A–C) hESCs were cultured as embryoid bodies in
the presence of 2 mM Dorsomorphin and 10 mM
SB43152 for 12 days, plated, and immunostained
for Pax6 (A), nestin (B), and Emx1 (C) (all red; blue
is Hoechst 33258). Scale bars represent 50 mm.
(D–F) Cells were cultured adherently for a further
10 days and immunostained for bIII-tubulin (D) and
Tbr1 (E) or V-GLUT1 (F). Scale bars represent
50 mm.
(G–I) Neuralized embryoid bodies were plated with
and without 2 mM aPKC pseudosubstrate inhibitor
peptide (G), with and without 500 mM metformin
(H), or with 500 mM metformin plus or minus the
aPKC inhibitor (I) for 4 days, immunostained for
bIII-tubulin, counterstained for Hoechst 33258,
and the relative proportion of bIII-tubulin-positive
neurons was determined. In (G), numbers of
control neurons in each experiment were normal-
ized to 100%. *p < 0.05, ***p < 0.001; n = 3 inde-
pendent experiments.
Error bars represent SEM.
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Metformin Enhances Neurogenesis via aPKC-CBP(Figure 4C). To ask whether these precursors would generate
neurons, we differentiated them for 10 days in neural induc-
tion medium (see Experimental Procedures). Immunostaining
showed that the Pax6-positive cells were replaced by morpho-
logically complex glutamatergic neurons that expressed bIII-
tubulin (Figure 4D), the glutamatergic neuron marker VGLUT1
(Figure 4F), and the cortical neuron marker Tbr1 (Fig-
ure 4E). Thus, as reported for murine ESCs (Bibel et al., 2007),
in the absence of specific inductive signals, neuralized hESCs
make forebrain radial precursors that generate glutamatergic
neurons.
To ask whether aPKCs were important for human neurogene-
sis, we cultured dissociated hESC-derived neural precursors
with or without the myristoylated aPKC peptide inhibitor for
4 days. This inhibitor had no effect on total cell number (quanti-
fied as cells/field; p > 0.05), but it decreased bIII-tubulin-positive
neurons by almost 2-fold (Figure 4G). We then asked whether
metformin enhanced neurogenesis by activating aPKC in human
forebrain precursors. Cells were grown for 4 days with or without
metformin plus or minus the myristoylated aPKC inhibitory
peptide. This analysis showed that 500 mM metformin signifi-
cantly increased bIII-tubulin-positive newly born neurons (Fig-
ure 4H) and that inhibition of the aPKCs abolished this increase28 Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc.(Figure 4I). Thus, as seen with murine
precursors, metformin acts via aPKCs to
promote human neurogenesis in culture.
Metformin Promotes Neurogenesis
from Adult Forebrain Neural
Precursors
To determine whether metformin also
regulates adult neurogenesis, we studied
neural precursor cells (NPCs) in the lateral
ventricle SVZ, because some of these
derive from embryonic cortical precur-sors (Merkle et al., 2004). Initially, we confirmed that forebrain
NPCs express aPKCs, taking advantage of the fact that they
will expand as neurospheres in culture. Immunostaining of
primary SVZ neurospheres showed that most cells displayed
aPKC immunoreactivity in both the cytoplasm and nucleus
(Figure 5A). We confirmed that this was also true in vivo by
immunostaining coronal sections through the adult cortex.
Detectable aPKC immunoreactivity was seen in many neurons
and white matter tracts, as previously reported (Naik et al.,
2000; Oster et al., 2004) and was also observed in GFAP-
positive cells within the SVZ (Figures S4A and S4B), probably
type B NPCs.
Forebrain NPCs normally generate interneurons for the olfac-
tory bulb. We therefore asked whether metformin increased
olfactory neurogenesis; adult mice were injected with BrdU five
times at 3 hr intervals to label dividing cells andwere then treated
with 200 mg/kg metformin daily for 21 days. Immunostaining of
serial sections through the main olfactory bulbs of these mice
(Figure 5B) showed that metformin significantly increased the
number of BrdU-positive, NeuN-positive olfactory neurons in
the granule cell layer (Figure 5C). We then asked whether metfor-
min had any impact on the number of SVZ NPCs. Mice were in-
jected with metformin daily for 7 days and coinjected with
AB
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F
Figure 5. Metformin Promotes Neurogenesis in the Adult Murine
Olfactory Bulb
(A) Primary passage adult SVZ neurospheres immunostained for total aPKCs
(red; blue is Hoechst 33258). Control was immunostained with normal rabbit
IgG and the same secondary antibody. Arrows denote aPKC-positive cells.
Scale bar represents 20 mm.
(B) Immunostaining for BrdU (green) and NeuN (red) in coronal sections
through the main olfactory bulb of mice injected with BrdU five times at 3 hr
intervals and treated with 200 mg/kg metformin or PBS (Control) daily for
21 days. Right panels are higher magnifications of the boxed areas. Arrows
denote double-labeled cells. Scale bars represent 200 mm (left) and 50 mm
(right).
(C) Total number of BrdU-positive, NeuN-positive newborn neurons in control
versus metformin-treated olfactory bulbs as determined from sections similar
to those in (B). **p < 0.01; n = 5 animals each.
(D) Immunostaining for BrdU (green) and Ki67(red) in coronal SVZ sections of
mice injected with 200 mg/kg metformin or PBS (Control) daily for 7 days, and
coinjected with BrdU on the seventh day, 24 hr prior to analysis. Right panels
show higher magnifications of the boxed areas. Arrows denote double-labeled
cells. Scale bars represent 200 mm (left) and 50 mm (right).
(E and F) Quantification of BrdU-positive (E) or BrdU and Ki67 double-positive
(F) cells in the SVZ of control versus metformin-treated animals, determined
from four anatomically matched coronal sections similar to those shown in (D).
**p < 0.01; n = 5 animals each.
Error bars represent SEM. See also Figure S4.
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Metformin Enhances Neurogenesis via aPKC-CBP100 mg/kg BrdU on the final day. Analysis of coronal forebrain
sections 24 hr later demonstrated that metformin significantly
enhanced the number of BrdU-labeled cells (Figures 5D and
5E) and the number of cells double-labeled for BrdU and Ki67
(Figures 5D and 5F) over this time frame. Thus, metformin
enhanced adult forebrain neurogenesis.
Metformin Enhances Hippocampal Neurogenesis
in a CBP-Dependent Fashion
Because metformin enhanced the genesis of olfactory neurons,
we asked whether it also increased adult hippocampal dentate
gyrus neurogenesis. Immunostaining of hippocampal sections
showed that aPKCs were detectably expressed in most dentate
gyrus cells (Figure S4C) including some GFAP-positive cells
within the subgranular zone (SGZ; Figure 6A), probably adult
NPCs. We therefore asked whether metformin enhanced
hippocampal neurogenesis; adult mice were injected daily with
metformin and BrdU for 3 days, and then were injected with met-
formin alone for 9 additional days. Immunostaining of hippo-
campal sections (Figure 6B) demonstrated that metformin
significantly increased the number of BrdU-positive, NeuN-
positive newly born granule neurons by approximately 30% (Fig-
ure 6C). Consistent with this, we observed an increase in cells
expressing doublecortin, a marker of newborn neurons (Figures
6D and 6E). Thus, metformin enhanced adult hippocampal
neurogenesis.
We also askedwhethermetformin had an impact on the hippo-
campal NPC pool, immunostaining sections from the same
experiments for BrdU and for GFAP, which is expressed in
SGZ NPCs and in astrocytes in the hilus. This analysis showed
that metformin did not significantly change GFAP-positive,
BrdU-positive NPCs in the SGZ (Figure 6F). It also showed that
virtually all of the GFAP-positive, BrdU-positive cells were
located in the SGZ, with very few double-labeled hilar astrocytes
in either controls or metformin-treated animals (an average of
two versus seven cells/dentate gyrus in control versus metfor-
min-treated mice). We did not detect BrdU-positive cells coex-
pressing the oligodendrocyte marker GalC in either control or
metformin-treated hippocampi. To confirm that metformin did
not alter NPC pools, we injected mice with metformin daily for
7 days and coinjected them with BrdU on the final day (Fig-
ure 6G). Immunostaining of serial sections showed that this
treatment did not alter the number of proliferating BrdU- and
Ki67-positive cells (Figure 6H).
Our culture data indicate that metformin promotes neurogen-
esis via an aPKC-CBP pathway. To ask whether the same
pathway is important in vivo, we used mice that are heterozy-
gous for CBP (Kung et al., 2000). Previous work indicates that
the adult brain in cbp+/mice is morphologically normal (Alarco´n
et al., 2004; Wang et al., 2010), as is basal hippocampal neuro-
genesis (Lopez-Atalaya et al., 2011).We first confirmed this latter
finding by administering BrdU for 3 days to 2-month-old cbp+/+
and cbp+/ littermates. Quantification of BrdU/NeuN-positive
newborn neurons 9 days later showed that basal hippocampal
neurogenesis was similar in mice of both genotypes (Figure
6J), as reported (Lopez-Atalaya et al., 2011). We then asked
whether metformin required normal levels of CBP to enhance
hippocampal neurogenesis. Seven-month-old cbp+/+ and
cbp+/ littermates were treated with metformin and BrdU forCell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc. 29
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Figure 6. Metformin Promotes Neurogene-
sis in the Adult Murine Hippocampus in
a CBP-Dependent Fashion
(A) Confocal image of a coronal adult dentate
gyrus section immunostained for total aPKC (red)
and GFAP (green). Arrows denote a double-
labeled cell in the SGZ. The control was immuno-
stained with normal rabbit IgG and the same
secondary antibody. Scale bar represents 20 mm.
(B) Coronal hippocampal dentate gyrus sections
frommice injected with metformin or PBS (control)
daily for 12 days, with BrdU coinjection for the first
3 days. Sections were immunostained for BrdU
(green) and NeuN (red), and insets show higher
magnifications of the boxed areas. Scale bar
represents 200 mm.
(C) Total number of BrdU-positive, NeuN-positive
newborn neurons in PBS (Control)- versus met-
formin (Met)-treated hippocampi determined from
sections as in (B). ***p < 0.001; n = 9 animals each.
(D) Hippocampal dentate gyrus coronal sections
from adult mice treated as in (B) and immuno-
stained for doublecortin (DCX). Arrows denote
positive cells. Scale bar represents 50 mm.
(E) Total number of doublecortin-positive neurons
in PBS (Control)- versus metformin (Met)-treated
hippocampi determined from sections as in (D).
*p < 0.05; n = 9 animals each.
(F) Total number of BrdU-positive, GFAP-positive
cells within the SGZ of PBS (Control)- versus
metformin (Met)-treated hippocampi determined
from sections similar to those in (B) that were
immunostained for GFAP rather than NeuN. p >
0.05; n = 5 animals each.
(G) Immunostaining for BrdU (green) and Ki67 (red)
in coronal dentate gyrus sections of mice injected
with PBS (Control) or metformin (Met) daily for
7 days and coinjected with BrdU on the last day.
The insets show the boxed areas at higher
magnification. Scale bar represents 100 mm.
(H) Total number of BrdU and Ki67 double-positive
cells in the SGZ of PBS (Control) and metformin
(Met)-treatedmice, determined from sections as in
(G). p > 0.05; n = 5 animals each.
(I) Coronal dentate gyrus sections of 7-month-old
cbp+/+ and cbp+/mice injected with metformin or
PBS (control) daily for 12 days, with BrdU co-
injection for the first 3 days. Sections were immunostained for BrdU (green) and NeuN (red). The insets show the boxed areas at higher magnification. Scale bar
represents 200 mm.
(J) Total number of BrdU-positive, NeuN-positive newborn neurons in hippocampi of 2-month-old cbp+/+ versus cbp+/ littermates. Mice were injected with BrdU
for 3 consecutive days and analyzed as in (I) 9 days later (n = 4 animals each, p > 0.05).
(K and L) Total number of BrdU-positive, NeuN-positive (K), and doublecortin-positive (L) newborn neurons in PBS (Control)- versus metformin (Met)-treated
cbp+/+ versus cbp+/ hippocampi from 7-month-old mice, determined from sections as in (I) and (D). *p < 0.05; n = 4–5 animals each.
Error bars represent SEM.
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Metformin Enhances Neurogenesis via aPKC-CBP3 days and then metformin alone every day for 9 additional days.
Immunostaining (Figure 6I) showed that although basal neuro-
genesis was decreased at this age, metformin still enhanced
hippocampal neurogenesis in the wild-type cbp+/+ mice (Fig-
ure 6K). In contrast, metformin did not enhance neurogenesis
in mice that were haploinsufficient for CBP (Figure 6K). This
conclusion was confirmed by quantifying doublecortin-positive
newly born neurons in these hippocampi (Figure 6L). Thus, met-
formin promotes neurogenesis by activating an aPKC-CBP
pathway both in culture and in vivo.30 Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc.Metformin Enhances Spatial Memory Formation
Adult neurogenesis in the hippocampus plays a key role in spatial
memory function, regulating acquisition of a spatial memory and
subsequent flexible use of that spatial memory (Dupret et al.,
2007; Garthe et al., 2009; Stone et al., 2011). We therefore devel-
oped a hidden platform version of the water maze task where
mice were asked to acquire an initial platform location and
then to rapidly learn a second platform location (Figure 7A). To
determine whether metformin had any effect on learning in this
paradigm, we injected adult mice with metformin (200 mg/kg)
* **
***
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Figure 7. Metformin Treatment Enhances
Spatial Memory Formation in Adult Mice
(A) Schematic of the BrdU, metformin, and TMZ
injections relative to the time course of training
and testing protocols for the Morris water maze
experiments. Metformin or sterile saline (as a
control) were injected daily for the 38 day
period and a subset of mice were coinjected with
BrdU as indicated. Some mice also received
injections of TMZ or vehicle at the indicated time
points.
(B) Acquisition of the initial platform location
across 5 days of training with latency to reach the
platform as a measurement of learning. Metformin
and control groups were similar in the initial
acquisition of the task (2-way ANOVA: group
F(1,279) = 0.662, p = 0.42; training day F(1,279) =
34.311, p < 0.001; group X training day interaction
F(4,279) = 0.734, p = 0.57; n = 56).
(C) Acquisition of the platform location after it was
moved to the opposite quadrant of the pool. Both
metformin and control groups acquired the new
location at equivalent rates (2-way ANOVA: group
F(1,111) = 1.752, p = 0.19; training day F(1,111) =
17.727, p < 0.001; group X training day interaction
F(1,111) = 0.325, p = 0.57; n = 56).
(D) After acquisition of the new location, the
platform was removed and mice were given
a 60 s probe trial. Both the control and the
combined metformin- and metformin/vehicle-
treated groups showed significant differences
between the time spent in the different quadrants
by one-way ANOVA. Post-hoc analysis showed
that the metformin/metformin plus vehicle-
treated mice searched selectively in the target
quadrant relative to all the other quadrants (one-
way ANOVA, F(3,111) = 11.6, ***p < 0.0001;
training quadrant > all other quadrants, p < 0.05;
n = 14 each of metformin and metformin plus
vehicle, combined because they were not sig-
nificantly different) while the control mice only
searched significantly more in the target quad-
rant relative to the adjacent left quadrant (one-
way ANOVA, F(3,111) = 3.202, *p = 0.02; training
quadrant > adj l quadrant, p < 0.05; n = 28). In
contrast to these two groups, the Met/TMZ group
showed no significant preference for the training
quadrant relative to the other three quadrants (one-way ANOVA, F(3,51) = 2.4, p = 0.07; for the training quadrant relative to all other quadrants, n.s. p > 0.05;
n = 13).
(E) Relative to control mice, the metformin-treated mice also spent a significantly greater amount of time searching in the quadrant containing the new platform
location (t(55) = 4.277, p = .04; n = 28 in each group) and significantly less time in the opposite quadrant where the target had been previously located (t(55) = 4.036,
p = 0.05; n = 28 in each group).
(F–H) Coronal dentate gyrus sections of mice treated with metformin or sterile saline (Control) as in (A) and injected with BrdU at the start of the experiment were
analyzed anatomically by immunostaining for BrdU and NeuN (as in Figure 6B), and these sections were quantified for the total number of BrdU-positive cells (F),
newly born BrdU-positive, NeuN-positive neurons (G), and BrdU-positive, NeuN-negative cells (H). **p < 0.01, ***p < 0.001; n = 5 animals each.
(I) Coronal dentate gyrus sections similar to those in (F)–(H) were analyzed by immunostaining for doublecortin (as in Figure 6D), and these sections were
quantified for the total number of doublecortin-positive neurons. *p < 0.05; n = 5 animals each.
(J) Mice treated with metformin plus vehicle or metformin plus TMZ as in (A) were injected with BrdU at day 38 and coronal dentate gyrus sections were analyzed
1 day later by immunostaining for BrdU. The graph shows quantification of the number of BrdU-positive proliferating cells in these sections. **p < 0.01; n = 5
animals each.
Error bars represent SEM. See also Figure S5.
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Metformin Enhances Neurogenesis via aPKC-CBPor control (sterile saline) daily for 38 days, coinjecting some
animals with BrdU on days 5, 6, and 7 to assess neurogenesis.
From 22 to 38 days,micewere trained and assessed in this water
maze task (Figure 7A). Metformin did not affect body weight over
this time course (Figure S5A). Behavioral analysis showed thatthemetformin and control groups were similar in their acquisition
of the initial platform location (Figure 7B) and that this initial
spatial memory was stable in both groups, as assessed by probe
tests 1 day and 1 week after completion of training (data not
shown). Mice were then assessed on their ability to learn theCell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc. 31
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Metformin Enhances Neurogenesis via aPKC-CBPnew platform location in the reversal phase of this task. Both
groups were similar with regard to their rate of learning (Fig-
ure 7C), and both spent significantly longer in the target zone
than in the other zones (Figure 7D). However, during the probe
test, the metformin-treated mice spent significantly more time
in the quadrant containing the new target (Figure 7E) while the
control mice spent more time in the quadrant that had contained
the platform in the initial training phase (the opposite quadrant)
(Figure 7E). Both groups spent a similar amount of time in quad-
rants that had never contained either target (Figure 7D). Impor-
tantly, there was no difference between the two groups in the
distance traveled (Figure S5B) or swimming speed (Figure S5C).
Thus, metformin treatment selectively enhanced the ability to
update spatial memory, consistent with previous studies dem-
onstrating that neurogenesis is necessary for flexible memory
processes (Dupret et al., 2007; Garthe et al., 2009).
We then analyzed a subset of these animals anatomically to
ask whether the enhanced spatial memory formation was coinci-
dent with a long-term increase in dentate gyrus neurons. Immu-
nostaining demonstrated that 1month after BrdU injection, at the
completion of behavioral training, the large majority of the BrdU-
positive cells in the dentate gyrus were NeuN-positive neurons
(compare Figures 7F and 7G). Moreover, the total number of
BrdU-positive cells was increased by the metformin treatment
(Figure 7F) as was the total number of BrdU-positive, NeuN-
positive neurons (Figure 7G). In contrast, the number of BrdU-
positive, NeuN-negative cells (presumably primarily NPCs) was
unaltered (Figure 7H). Consistent with these findings, the number
of doublecortin-positive cells was also increased (Figure 7I).
Thus, metformin promotes the genesis of new hippocampal
neurons and these neurons survive in the long term.
These results demonstrate a correlation between ametformin-
induced increase in hippocampal neurogenesis and enhanced
spatial learning. To ask whether this was a causal relationship,
we took advantage of the fact that the only rapidly proliferating
cells in the brain are NPCs. We therefore used the drug temozo-
lomide (TMZ), a DNA alkylating agent that selectively induces the
death of replicating cells, to decrease NPC numbers and ask
whether this inhibited the metformin-induced increase in spatial
memory. We and others have previously used this approach in
adult neurogenesis studies (Garthe et al., 2009; Stone et al.,
2011). To perform these experiments, we used the samemetfor-
min administration and training regimen but injected mice with
25 mg/kg TMZ for 6 cycles of 3 days on and 4 days off, starting
from the first day of metformin injection throughout the training
regimen (Figure 7A). As controls, mice were treated in the same
way but were injectedwith vehicle rather than TMZ. Both of these
groups were able to acquire the initial platform location in the
water maze, and this initial memory was stable, as indicated by
probe tests 1 day and 1 week later (Figures S5D and S5E). Anal-
ysis of the reversal phase of the water maze task demonstrated
that the performance of metformin/vehicle-treated mice was
similar to mice treated with metformin alone (p > 0.05). In
contrast, mice treated with metformin and TMZ were impaired
with regard to learning the new platform location, showing no
preference for the training quadrant over the other quadrants
(Figure 7D). Thus, although TMZ did not affect the ability of
mice to learn the initial platform location, it blocked metformin’s
ability to promote enhanced learning on the reversal task.32 Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc.To ensure that the TMZ regimen decreased the proportion
of proliferating precursors in the hippocampus, we injected
a subset of mice with BrdU immediately after the reversal task
probe test. Analysis of hippocampi 24 hr later demonstrated
that metformin/TMZ-treated mice had only approximately half
as many BrdU-positive cells as did metformin/vehicle-treated
mice (Figure 7J), confirming the efficacy of this treatment regime.
Thus, inhibition of adult neurogenesis impairs metformin’s ability
to enhance spatial learning.
DISCUSSION
The findings presented here demonstrate that the widely used
diabetes drug metformin is sufficient to activate the aPKC-CBP
pathway in neural precursors and to thereby enhance neurogen-
esis and raise the possibility that metformin could provide the
basis for a therapeutic strategy for the human nervous system.
Specifically, these findings support five major conclusions. First,
this work demonstrates that aPKCs z and i play essential but
distinct roles in regulating the genesis of neurons from radial
precursors during embryonic development. aPKCz regulates
the differentiation of radial precursors into neurons by activating
CBP, whereas aPKCi regulates the transition from radial precur-
sors to basal progenitors, presumably by acting as part of the
apical polarity complex (Costa et al., 2008). Second, by using
a hESC-based approach for generating developing neural
precursors, we show that aPKCs are also essential for human
forebrain neurogenesis, at least in culture. Third, we show that
metformin activates the aPKC-CBP pathway in neural precur-
sors and that this activation promotes genesis of both human
and rodent neurons in culture. Fourth, we show that metformin
also promotes neurogenesis in the adult brain, enhancing the
number of newly born neurons in both the olfactory bulb and
the hippocampus. This adult neurogenesis requires CBP; when
CBP is haploinsufficient, basal neurogenesis is unaffected, but
metformin-induced neurogenesis is completely inhibited. Fifth,
our behavioral studies demonstrate that metformin enhances
spatial memory function coincident with a long-term increase
in the number of newly born adult dentate gyrus neurons.
When this metformin-induced neurogenesis is inhibited with
the pharmacological agent TMZ, this also prevents the metfor-
min-associated facilitation of spatial memory. Thus, metformin,
by activating an aPKC-CBP pathway, recruits adult neural
precursors and enhances neural function, thereby providing
a candidate pharmacological approach for nervous system
therapy.
There is considerable interest in the idea that recruitment of
endogenous neural stem cells might provide a therapeutic
strategy, based upon two lines of investigation. First, it is now
clear that newly born adult neurons play a key role in the func-
tionality of both the olfactory system and the hippocampus
(Zhao et al., 2008). These findings are particularly relevant with
regard to the hippocampus, because this structure plays a key
role in normal cognition and is preferentially vulnerable in disor-
ders such as ischemic stroke and Alzheimer’s disease. Second,
growing evidence indicates that adult neural stem cells are re-
cruited in the injured and degenerating brain and that this repre-
sents an attempt at endogenous repair. Although the functional
importance of this recruitment is still an open question, it is clear
Cell Stem Cell
Metformin Enhances Neurogenesis via aPKC-CBPthat adult neural stem cells generate new neurons and oligoden-
drocytes in a number of neural injury paradigms (reviewed in
Kernie and Parent, 2010), raising the hope that if this response
could be enhanced, then perhaps it would promote repair.
However, clinical approaches for recruiting adult neural stem
cells in humans are currently lacking.
The search for pharmacological agents that can activate
endogenous adult stem cells has led to a number of recently
published chemical screens (reviewed in Li et al., 2012). Here,
we have taken a different approach; we have defined an
aPKC-CBP signaling pathway that is important for neural
precursor differentiation (Wang et al., 2010; data presented
here) and then focused upon a widely used drug, metformin,
that activates this pathway in liver cells (He et al., 2009). In this
regard, our data indicate that metformin does indeed activate
the aPKC-CBP pathway to promote neurogenesis and that
it coincidentally enhances hippocampus-dependent spatial
memory formation, something that is thought to depend upon
adult neurogenesis (Garthe et al., 2009). Equally importantly,
we have shown that metformin has a similar activity on human
neural precursors, increasing the likelihood that it might enhance
neurogenesis in the human brain, as it does in the rodent.
Our findings also provide insights into the molecular mecha-
nisms regulating neurogenesis. Our previous work demon-
strated that CBP, a transcriptional coactivator and histone ace-
tyltransferase, enhanced differentiation of developing radial
precursors by binding to and acetylating genes that were impor-
tant for neuronal and glial differentiation. This required CBP
phosphorylation by aPKCz, presumably when this kinase was
itself activated in response to extrinsic stimuli. Here, we show
that aPKCz knockdown decreases neurogenesis and increases
the maintenance of radial precursors. Moreover, we show that
this phenotype can be rescued by expression of a CBP phos-
phomimic. Thus, activation of an aPKCz-CBP pathway is essen-
tial for radial precursor differentiation, and our inhibition and
knockdown studies indicate that metformin mediates its pro-
neurogenic effects by activating this pathway. In contrast, for
aPKCi, we show that it regulates neurogenesis but not gliogen-
esis in a CBP-independent fashion and that it enhances the tran-
sition from radial precursors to basal progenitors in vivo, thereby
indicating a different role for this isoform. These findings are
consistent with previous studies (Imai et al., 2006; Costa et al.,
2008; Bultje et al., 2009) indicating that aPKCi is an essential
component of an apical adherens/polarity complex that serves,
in part, to maintain radial precursors. Thus, aPKCs z and i play
distinct and important roles in neural precursors.
Our in vivo studies demonstrate that metformin enhances neu-
rogenesis in a CBP-dependent fashion in adult mice and our
behavioral work suggests that the increase in hippocampal
neurons is functionally relevant. In particular, we show that
metformin preferentially enhances the reversal phase of the
water maze task, and our data using TMZ to pharmacologically
deplete adult precursors suggests that it does so by promoting
genesis of new hippocampal neurons. In this regard, the speci-
ficity of the behavioral response is intriguing, because it raises
the possibility that the initial acquisition of a spatial memory
might have a somewhat different underlying neural substrate
than the acquisition of a second, related spatial memory, with
the latter involving newborn neurons.Metformin is widely used in humans as a treatment for type II
diabetes and other metabolic disorders. Intriguingly, there is
widespread interest in using metformin in individuals with
early-stage Alzheimer’s disease because an increasing propor-
tion of these individuals are also diabetic, and hyperinsulinemia
may enhance the onset and progression of neurodegeneration.
In this regard, a recent retrospective study indirectly suggested
that metformin might improve some of the adverse neu-
roanatomical outcomes associated with AD (Beeri et al.,
2008). Moreover, metformin has been shown to increase life-
span and delay the onset of cognitive impairment in a mouse
model of Huntington’s disease (Ma et al., 2007). Thus, while
metformin may have other actions in the nervous system, our
findings raise the possibility that its ability to enhance neuro-
genesis might have a positive impact in at least some nervous
system disorders.
EXPERIMENTAL PROCEDURES
Animals
All animal use was approved by the Animal Care Committee of the Hospital for
Sick Children in accordance with the Canadian Council of Animal Care poli-
cies. CD1 and C57BL/6 mice were obtained from Charles River Laboratory.
C57/129J mice, which were used for the behavioral tests, were bred at the
Hospital for Sick Children. All mice were maintained on a 12 hr light/12 hr
dark cycle with ad libitum access to food and water. Mice were used at
2 months of age unless indicated otherwise, and behavioral procedures
were conducted during the light phase of the cycle. B6.126S6-Crebbptm1Dli
mice (cbp+/ mice) were obtained from The Jackson Laboratory and main-
tained as described (Wang et al., 2010).
Cell Culture Analysis
E11.5–E12.5 cortical precursors were isolated from CD1 embryos and
cultured, transfected, and immunostained as described (Wang et al., 2010;
Supplemental Information) at a plating density of 150,000–180,000 cells/ml.
CNTF (50 ng/ml; Cedarlane Laboratories) and neuregulin-b (100 ng/ml;
R&D Systems) were added 1 day after plating. Myristoylated aPKC peptide
(2 mM; Calbiochem) and metformin (Sigma-Aldrich) were used as indicated.
For quantification, more than 400 cells per condition in at least 8 randomly
chosen fields per experiment were counted. Primary adult SVZ neuro-
spheres were cultured as described (Fujitani et al., 2010). HEK293 cells
were grown and transfected as described (Fujitani et al., 2010; Supplemental
Information).
In Utero Electroporation
In utero electroporations and immunostaining were performed as described
(Wang et al., 2010) with E13/E14 CD1 mice. For quantification, three to four
fields per coronal section from each of four anatomically matched sections
per brain were analyzed on a Zeiss Pascal confocal microscope, as previously
described (Wang et al., 2010). Amean of four scans taken with a 403 objective
were computed for each image.
Maintenance and Differentiation of hESCs
Undifferentiated HES2 cells were maintained in hESC medium as described
(Kennedy et al., 2007) and prior to neural differentiation were depleted of
feeder cells by culturing on Matrigel (BD Biosciences)-coated plates for 24
to 48 hr. Neuralized embryoid bodies (EBs) were generated by culturing small
aggregates of feeder-depleted hESCs in low cluster plates (Corning Inc.) in
knockout DMEM, supplemented with penicillin/streptomycin, 2 mM gluta-
mine, 4 mM monothioglycerol, 50 mg/ml ascorbic acid (Sigma Aldrich), 5%
N2 supplement (GIBCO), 5% B27 (GIBCO), and 20 ng/ml hbFGF at 37C in
an environment of 5%CO2, 5%O2, and 90%N2 for 24 hr. EBswere harvested,
washed, and cultured in the samemediumwith 2 mMDorsomorphin and 10 mM
SB43152 for a further 12 days and then gently dissociated and plated on poly-
d-lysine/laminin-coated plates in the same medium plus 20 ng/ml bhFGF,Cell Stem Cell 11, 23–35, July 6, 2012 ª2012 Elsevier Inc. 33
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fication, an average of 700 cells was counted per condition in 5–6 random
fields per independent experiment.
BrdU Labeling
Mice were treated with BrdU (Sigma-Aldrich) as described for the SVZ
(Morshead et al., 1998) and the hippocampus (Fujitani et al., 2010; Supple-
mental Information). For the hippocampus andmain olfactory bulb, every tenth
section was immunostained and quantitatively analyzed as described (Wojto-
wicz and Kee, 2006; Fujitani et al., 2010) and counts were normalized by multi-
plying for the total number of sections. For the SVZ, we quantified all cells
within two to three cell diameters of the ventricular surface from four anatom-
ically matched coronal sections from each animal.
Statistics
Statistical analyses were performed with a two-tailed Student’s t test or
ANOVA with Tukey’s multiple comparison post hoc analysis, unless otherwise
indicated. Error bars indicate the standard error of the mean (SEM).
Western Blot Analysis and Densitometry
Western blots were performed as previously described (Wang et al., 2010).
Antibodies are in Supplemental Information. Densitometry was performed
with Adobe (San Jose, CA) Photoshop.
Morris Water Maze
Two-month-old female C57/129J mice were used for all analyses and were
injected daily with metformin (200 mg/kg) or sterile saline for the entirety of
the experiment (Figure 7A). Some mice were also injected with 25 mg/kg
TMZ or 10% DMSO as indicated (n = 28 sterile saline alone, n = 14 metformin
alone, n = 14 metformin plus DMSO, and n = 13 metformin plus TMZ). Some
were also injected with BrdU as indicated. Mice were trained on the hidden
platform version of the water maze using a circular tank (120 cm diameter,
50 cm depth, 28C) filled with 40 cm of water made opaque with nontoxic
white paint. All testing was conducted under dim light. Extramaze visual
cues were located on curtains surrounding the maze. The escape platform
(10 cm diameter) was submerged 0.5 cm below the water surface. Acquisi-
tion was measured as latency to reach the platform and four possible start
locations were pseudorandomly assigned to each trial. Actimetrics tracking
software was used to record escape latency, swim speed, and distance
traveled. Each animal was given three 60 s trials to find the platform with
a 15 s intertrial interval across 5 days. After 5 days of training, mice were
administered immediate (1 day) and remote (1 week) memory probe tests
where the platform was removed and they searched for 60 s. Immediately
after these tests, the platform was moved to the opposite location and
animals were trained in the same manner for 2 additional days. The day after
this reversal training, mice were given a probe test where the platform was
removed and the amount of time spent searching in each quadrant was
measured.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/
j.stem.2012.03.016.
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